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Introduction: Two recent models are in use for analysis of allosteric drug action at receptor sites remote from
orthosteric binding sites. One is an allosteric two-state mechanical model derived in 2000 by David Hall. The other is an
extended operational model developed in 2007 by Arthur Christopoulos’s group. The models are valid in pharmacology,
enzymology, transportology as well as several other fields of biology involving allosteric concentration effects.
Results: I show here that Hall’s model for interactions between an orthoster, an alloster, and a receptive unit is the best
choice of model both for simulation and analysis of allosteric concentration-responses at equilibrium or steady-state.
Conclusions: As detailed knowledge of receptors systems becomes available, systems with several pathways and states
and/ or more than two binding sites should be analysed by extended forms of the Hall model rather than for instance a
Hill type exponentiation of terms as introduced in non-mechanistic (operational) model approaches; yielding
semi-quantitative estimates of actual system parameters based on Hill’s unlikely simultaneity model for G
protein-coupled receptors.Background
A sizeable decline in development of classical agonists
and antagonist for medication [1-3] has elicited a drug-
hunt to construct and develop allosters in laboratories of
academia [4-8] and industry (e.g., Novasite Pharmaceuti-
cals Inc; Addex Pharmaceuticals), including positive and
negative allosters as well as ortho-allosters for thera-
peutic purposes. In doing so, it has become important to
simulate and analyse concentration-response data for
allosters by models that are as close to the systems
mechanistic function as possible.
Optimal allosteric models are in great demand, since
mechanistic simulations may be combined with structural
analysis of alloster binding, receptor multi-merization and
association of molecules as G proteins, arrestins, and
RAMPs into synthesis of QSARs for ligand binding and re-
ceptor activation [9-16].
Data from equilibrium concentration-response experi-
ments involving allosteric modulators are presently
interpreted by unlike choices of model. Therefore, with
such schism in selection of model, especially true for
data from cell-systems expressing subtype 7TMRs [17],
it seems worth a discussion about which directionCorrespondence: bindslev@sund.ku.dk
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reproduction in any medium, provided the oranalysis of synagics data for allosters should take. For
possible outcomes of including allosters consult Figure 1.
For definitions of terms related to allostery see Table 1.
Two actual allosteric models - ATSM and EXOM. One
model is the allosteric two-state model, ATSM, intro-
duced by Hall in 2000, implemented and further dis-
cussed by others [5,17-25]. Another model we could call
the “extended operational model”, EXOM for short [26],
is based on combining the original operational model,
BLM [27], with the ternary-complex model, TCM [28],
as later further detailed [29-31]. EXOM is implemented
and presently advocated by several lead-modellers
[7,8,32-38]. There are other approaches taken to model
the behaviour of allosters in the field of 7TMRs
[20,33,39-42].
ATSM is a mechanistic model. ATSM-analysis with
extracted numbers for model parameters supposes direct
information about mechanical interactions between allos-
ters, receptors and orthosters at a molecular scale. Thus,
one might gain a quantitative and dynamic handle on
molecular processes per se within receptors. The other
model, EXOM, a non-mechanistic model, is a close
relative of ATSM and has the same number of inde-
pendent parameters to be determined. EXOM is used
assuming that individual physical parameters of multi-
step processes as such cannot be extracted, as they are
composite. EXOM may give quantified estimates onThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Phenotypic behavior of allosters. Panel A. Some
concentration-response curves with an alloster present demonstrating
enhancement and allo-inhibition of both a mixed and a competitive
type antagonism and with ceiling effects for all three. The red curve
represents an orthoster concentration-response in the absence of an
alloster. Panel B. Concentration-response relations with an alloster
present, displaying allo-agonism as a lifted initial activity with ceiling
and allo-synergy as a lifted maximal response. Both allo-agonism and
synergy curves are lifted compared to a concentration-response curve
with no alloster present as in the green curve. Definitions of
phenotypic alloster terms are listed in Table 1.
Table 1 Terms and definitions for allosteric synagics
(see Figure 1)
Term Definition
orthoster primary ligand, binds at orthosteric (primary)
receptor binding site and covers ligands as




secondary ligand, binds to a non-overlapping
(secondary or allosteric) binding site distinct
from an orthosteric binding site
ago-alloster an alloster which can activate the receptor
even in the absence of an orthoster, but with
ceiling for the increased activity
allo-agonism the effect of an ago-alloster
syn-alloster alloster, at high orthoster concentrations it can
still lift the response further with ceiling;
allo-synergy or synergy the effect of syn-allosters, different from
super-agonism
ago-syn-alloster alloster, both activates receptors in absence of
orthoster and increases activity even at high
orthoster concentration. Both increases in
activity have ceiling
allo-ago-synergy the effect of ago-syn-allosters, different from
super-agonism
enhancer alloster, moves orthoster d-r curves to the left
with ceiling
allo-competitor alloster, moves orthoster d-r curves right with
or without ceiling
allo-mixed-competitor alloster, decreases activity and changes
apparent affinity constants for orthosters.
Orthoster d-r curves with allo-mixed-competitor
are right-shifted but may have increased affinity
enhancer-inhibitor alloster that both increases apparent affinity
constants and decreases activity for orthosters.
With enhancer-inhibitor, orthoster d-r curves
move left with ceiling
ago-inverse-alloster alloster, stimulates activity from an allosteric site
in its own right, but with an activity which is




compound with moieties for simultaneous
binding and activation at both orthosteric and
allosteric receptor binding sites
synagics the study of equilibrium and steady-state
concentration-responses of ligand interactions




(PAMs* and NAMs**) - ligands that increase or
decrease receptor activity directly or indirectly
from an allosteric binding site.
*PAMs cover both ago-allosters, syn-allosters, and ago-syn-allosters. Enhancers
may be included here. ** NAMs cover both allo-mixed-competitors, enhancer-
inhibitors, and ago-inverse-allosters. Allo-competitors may be included here.
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and allosters interacting at receptors [26,34]. By selecting
similar assumptions for ATSM as for EXOM, ATSM may
cover the EXOM-scenario and yield estimates of para-
meters for lumped multi-steps rather than single steps,
and thus become a black-box model as the EXOM.
In both ATSM and EXOM, allosters may behave as
enhancers with ceiling and as competitive antagonists
without ceiling. Furthermore, they are also efficient in
simulating allo-agonism and allo-synergy both with ceil-
ing effects; observed as lifts of concentration-response
curves by allosters at low and high orthoster concentra-
tions [17,26,37]. However, EXOM lacks ATSM’s advan-
tage of being a mechanistic model and for describing
spontaneous activity of receptive units. Additionally,
from a theoretical point of view, a parameter in EXOM
to describe cooperative activity is amputated, yieldingillogic results. For this latter conclusion, see details in
the next to last sections of Methods and Results and
Discussion.
Here I focus on ATSM and EXOM and compare them
for simulation and analysis of experimental data. It is
demonstrated that there are no arguments as posited
[8,17] for employing EXOM instead of ATSM, quite
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ture modellers to use ATSM and possible extended forms
for analysis and simulation of allosteric concentration-
response relations rather than EXOM.
Methods
One basic model - cTSM
In simulation of synagics for orthosters and allosters, the
basis of most models is often two simple reaction
schemes; the cyclic-two-state model, cTSM, and the
ternary-complex model, TCM. Since this paper is about
modelling as opposed to general statements about
ligand-receptor interactions it is paramount with precise
definitions including aspects of cTSM and TCM. This
has been discussed before [22] and may seem superflu-
ous. However, in order to validate and compare newly
derived ATSM and EXOM in a coherent fashion, con-
cepts related to cTSM and TCM must be brought
together and systematized. cTSM is dealt with first.
The gist of the cTSM, Figure 2A, is its explicit descrip-
tion of a conformational switch between an inactive and
active state of a non-bound receptor. It specifically
includes spontaneous activity in form of non-liganded
receptor R*. The behaviour of cTSM has been scruti-
nized [43,44]. cTSM has two interesting parameters. L
describes the distribution between unliganded inactive
and active receptor states, R ⇌ R*, such that L = R*/R,
Figure 2A. Deriving cTSM’s distribution equation for ac-
tivity, the free non-active receptor state R is equated
with “1”. Thus, the unliganded, active receptor state R*













Figure 2 Two simple reaction schemes. Panel A. The cyclic two-state m
separate but simultaneous pathways from an inactive and non-liganded re
conformation R*S. As is an equilibrium association constant for S, L is a con
a is an efficacy constant for ligand bound receptor conformations from RS
represents the term and concentration for an additional alloster ligand. Am
cooperativity coefficient for two-ligand binding.constant for activation of receptor forms bound with lig-
and S, RS ⇌ R*S. This step has a⋅L as its efficacy
constant. By assuming multi-steps, a⋅L is identical to
Stephenson's efficacy constant [45] and Black & Leff ’s
transducer ratio τ [27]. As is the equilibrium affinity con-
stant for S binding to non-active forms of R, Figure 2A.
Therefore, a is also a concomitant constant for binding
of S to already activated receptors. The affinity constant
for S+R*⇌ R*S is thus a⋅As.
Arguments still appear on how to understand activation
of protein molecules when ligands are applied - is it by
induction after ligands bind or is it rather by ligand
selection and stabilization of already activated molecules?
Jacques Monod early on favoured a selection process [46]
and this understanding crystallized in the famous MWC-
model [47]. The MWC explicitly introduces an unliganded
switch R⇌R* as the “allosteric transition” [48]. Contrary,
Koshland argued for induction after binding [49]. “Selec-
tion” follows one leg of cTSM while “induction” follows
another [50], Figure 2A. They are two views on a single
process [18] chapter 5. Below, when either “induction” or
“selection” is used on activation of receptive units as
ligands bind, it covers both pathways in cTSM.
Another basic model - TCM
The TCM, Figure 2B, looks fairly simple, but possesses
surprising allosteric regimes. Depending on which of the
liganded complexes are included for activity, TCM can
simulate enhancement with ceiling and competitive
(“surmountable”) inhibition, besides allo-agonism with-











odel, cTSM, with selection and induction arrows indicating two
ceptor conformation R to an active and agonist S liganded receptor
formational efficacy constant for non-bound receptors, and parameter
to R*S. Panel B. The ternary-complex model, TCM, in which symbol M
is an equilibrium association constant for M, and parameter c is a
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spontaneous activity. Ten sub-models derived from
TCM are characterized in Table 2. Three of these sub-
models are further described in the Results section and
some simulations by these three models are shown in a
figure in the Results section.
Operational models
To understand the present use of “stimulus”, “efficacy”
and “intrinsic efficacy” in operational models as EXOM,
it is necessary to go back to their definitions [45,51,52].
Stephenson’s stimulus concept seems obsolete today by
accepting two-step receptor schemes with straightfor-
ward derived distribution equations [18] chapter 2; [50]
and when needed, apt assumptions of more than two
steps. Two-step schemes yield equations identical to
initially derived operational models based on the stimulus-
response idea [27,51,53]. Concepts as “stimulus”, “trans-
ducer ratio” and “fitting parameter” are of course justified
in selecting operational model approaches rather than
mechanistic ones. Spontaneous activity often seen in
studies with 7TMRs is not included in the realm of
operational models, although recently serious attempts
have appeared [54,55].
Meanwhile, users of operational models should
recognize that their assumptions for derivation put a veilTable 2 Phenotypic concentration-responses for allosters in 1
Type of TCM model # Enhancement← w/ ceiling← Allo-agonism ↑
(S)/4 1 no na no
(S+MS)/4 2 yes yes no
(S+M+MS)/4 3 yes yes yes
(S+M)/4 4 no na inverse
(MS)/4 5 (yes) yes no
(S)/3 6 no na no
(S+MS)/3 7 yes → no
(MS)/3 8 (yes) no no
(S)/3* 9 no na no
(S+M)/3* 10 no na yes
For model types in the left column, terms S, M, and MS in parenthesis indicate activ
total number of receptor conformations after the slash. In models 6–8, complex MR
models 9–10, complex MRS is not formed. **Model 9 is classical type II reaction sch
parameter c = 0. Arrows indicate direction of affinity change and direction of ceilin
na = not applicable, (yes) indicates that there is an effect in form of co-agonism, i.e
Simulations of concentration-response relations for tabulated sub-models 1–4, in co
alloster. Ceiling effects for enhancement (= parameter c > 1) in sub-model 2 starts a
< 1) in sub-model 2 requires c⋅Am⋅M > 10 for a ceiling effect to appear. Thus, sub-m
c⋅Am⋅M is below 10, Figure 4 panel F. This dependence on product Am⋅M > 1 for ce
allo-competitive inhibition are also characteristics of both ATSM, Figure 5 panels A
Tabulated ternary-complex sub-model 1 and 6 with parameter c < 1 are characterized
includes a possible simulation of classical non-competitive antagonism with a fixed EC
increasing affinity for increasing modifier concentration, indicated by EC50 ↓ in column
inverse agonism with decreasing ceiling values for the apparent affinity EC50 when par
panels J-L.
Sub-models 5 and 8 demonstrate co-agonism, which means that both ligand S and lig
Sub-model 7 is identical to the classical un-competitive reaction scheme. Sub-mode
excluding the double-liganded MRS conformation ([18] chapter 2), and therefore do
Two characteristics for ATSM and EXOM are not covered by any of the listed TCM r
and ceiling effects for allo-agonism, compare Figure 4 panels G-I with Figure 5 paneover underlying physical systems and that any involved
“operational” assumption may just as well be applied to
the ATSM. For instance, as mentioned, a⋅L can be con-
ceived as equal to transducer ratio τ.
Distribution equation for ATSM and EXOM
Reaction schemes of ATSM and EXOM are depicted in
Figure 3A and 3B. The intention with EXOM was to de-
rive a stimulus-equation for activating receptors, including
alloster-activated units, while explicitly excluding non-
liganded active conformations [26]. Thus, three bound
species RS, MR, and MRS in EXOM can switch to active
forms R*S, MR*, and MR*S. But, in order to exclude con-
stitutive activity, non-liganded R is not allowed a switch to
active R*, Figure 3B. Thus, EXOM is a pure “induction”
reaction scheme in Koshland-sense, as free forms of recep-
tor R must be bound before activation. The three bound
and active forms of the receptor are equated as “stimulus”
and transformed through a hyperbolic expression for ac-
tivity, as for the BLM. The result is a distribution equation
with three active conformations to a total of seven con-
formation, as even a possible inactive R*-conformation is
considered non-existent [26].
To simplify a comparison of EXOM with ATSM, dis-
tribution equations for both are expressed parallel to
earlier expressions for ATSM [18] chapter 7.0 sub-models from TCM
w/ ceiling ↑ Strict allo-synergy ↑ Allo-modification w/ ceiling→ ↓










e forms of the liganded receptor as either R*S, M*R or MR*S, and with the
is not formed. Model 7 is the classical uncompetitive reaction scheme. * In
eme for competitive inhibition with no ceiling, the same as assuming
g effects.
., no response for ligand S alone.
lumn 2, are shown in Figure 4 panels A-I. S stands for orthoster and M for
t Am⋅ M > 1, panel D in Figure 4. Allo-competitive antagonism (= parameter c
odel 2 simulates genuine competitive antagonism as long as the product
iling effects of enhancement and on product c⋅Am⋅M >10 for ceiling effects in
and C, and EXOM, Figure 5 panels D and F.
as (mixed) modifier mechanisms in enzymology. Their mixed allo-modification
50, when c = 1, Figure 4 panel B. Furthermore, both sub-models 1 and 6 have
8. Sub-type model 4, excluding the ternary complex MRS as active, may show
ameter c > 1 and increasing ceiling levels for EC50 when parameter c < 1, Figure 4
and M have to be present for an activity to show up, simulations not shown.
ls 9 and 10 are based on the classical type II competitive reaction scheme,
not qualify as true TCMs.
eaction schemes in Table 2, viz. a strict allo-synergy, Figure 5 panels M and N,
ls G-H, J-K, M-N, Q-R, and T-U.
Figure 3 Reaction schemes of the allosteric two-state model,
ATSM, and the extended operational model, EXOM. Panel A.
The ATSM. Panel B. The EXOM. The models are presented with their
basic simpler reactions schemes as the cTSM and TCM from
Figure 2. The cubic ATSM has eight receptor conformations while
the EXOM only has seven of those, as the spontaneous active
represented by receptor conformation R* is excluded. The two
models have the same total number of parameters, seven in all.
Besides parameters defined in Figure 2, ATSM and EXOM have
parameter b, an efficacy constant when the alloster M-bound
receptor is activated, and parameter d a cooperativity efficacy
constant involving two ligands. The constants L, As, Am , a and c are
given as in Figure 2, and EXOM has a slope factor n, not shown.
E ¼ Em⋅ a⋅As⋅Sþ b⋅Am⋅Mþ a⋅c⋅d⋅As⋅S⋅Am⋅M½ 
nð Þ
1þ As⋅Sþ Am⋅Mþ c⋅As⋅S⋅Am⋅M½  nð Þ þ a⋅As⋅Sþ b⋅Am⋅Mþ a⋅c⋅d⋅As⋅S⋅Am⋅M½  nð Þ
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1þ As⋅Sþ Am⋅Mþ c⋅As⋅S⋅Am⋅Mþ L⋅ð Þ 1þð Þa⋅As⋅S½and for activity in ATSM:Deviations between the two models are marked by
bracketed and bolded symbols. Definitions of symbols
listed below are followed by symbols in parenthesis from
Leach [26] and Hall [22]: E = actual response; Em = max-
imal activity; S = orthoster (A; A); M = alloster (B; B); As =
equilibrium association constant for ligand S (1/KA , K);
Am = equilibrium association constant for ligand M (1/KB,
M ); a = efficacy constant for S (τA; α); b = efficacy con-
stant for M (τB; β); c = binding cooperativity constant (α;
γ); and d = activation cooperativity constant (β; δ). Param-
eter β for EXOM is only defined for cooperativity of an
alloster on orthoster activation, but not reciprocally as in
ATSM. Further, unlike ATSM, EXOM has a Hill type ex-
ponentiation parameter, n, for terms of summed activity
and inactivity. The benefits of including such a Hill expo-
nentiation may be questioned as discussed earlier [18]
chapter 10. Indeed, Hill-type exponentiation may also be
applied to ATSM. However, as ATSM is a mechanistic ap-
proach, it seems more logical to derive equations based on
formulation for an extended ATSM with more than two
binding sites [18,25].
In absence of an orthoster the initial efficacy, IntEff,
for ATSM is given by: L/[L+(1+ Am⋅M)/ (1+b⋅Am⋅M)],
and for EXOM, assuming n = 1, by: 1/[1+(1+Am⋅M)/
(1+b⋅Am⋅M)].
For high values of the orthoster, S⇒∞, maximum activity,
MaxEff, as a function of alloster concentration for ATSM is
given by: L/[L + (1 + c ⋅Am ⋅M)/(a ⋅ (1 + b ⋅ c ⋅ d ⋅Am ⋅M))],
and for EXOM, assuming n = 1, by: 1/[1 + (1 + c ⋅Am ⋅M)/
(a ⋅ (1 + c ⋅ d ⋅Am ⋅M))]. Differences between ATSM and
EXOM expressions are indicated with bolded types.
Best-fit analyses to experimental data for ATSM and EXOM
The analyses were performed in the following manner.
Selected allosteric effects were obtained from data-
figures in the literature, data-figure 1 ([38], Figure 2B),
data-figure 2 ([37], Figure 2B), and data-figure 3 ([56],
Figure 3). Model parameters a and As were first evalu-
ated by fitting the distribution equations for ATSM andb⋅ð Þc⋅d⋅As⋅S⋅Am⋅M
þ b⋅Am⋅Mþ a⋅ b⋅ð Þc⋅d⋅As⋅S⋅Am⋅M
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The obtained values for a and As were then inserted into
the distribution functions for the two models and used
for an ensuing fitting of the remaining parameters listed
in the last Table, parameters b, c, d, and Am. By varying
the initial values for each parameter in three steps, at
least 12 fits were performed on each curve for every
alloster concentration in all three data-figures. Only fit-
ted parameter values with convergence to a tolerance of
10-10 in SigmaPlot software were accepted.
Thus, concentration-response curves at three different
alloster concentrations yields three best-fit values for
each of the four parameters. Obtained results for the
single parameter in the last Table represent a ratio be-
tween the two best-fit values with the largest mutual dif-
ference of the three determinations for each parameter
at different alloster concentrations. A global fit to data
sets for all four parameters [57] was not possible.
A fourth data set, data-figure 4 ([36], Figure 1C), was
also analysed but neither ATSM nor EXOM fitted well
to these data with a 44% spontaneous activity and a
56% alloster/ orthoster response. The failure of fitting
was mostly due to a lack in obtaining a reasonable
determination of maximal response for several of the
concentration-response curves.
Results and discussion
TCM - three and ten variants
Three functional variants of TCM are briefly described
below and examples of their simulations shown in Figure 4,
while characteristics of ten different forms derived from
TCM are listed in annotated Table 2.
In a first form, complex RS tacitly moves to R*S as the
sole source of activity. Simulation of this allo-scheme
can resemble classical non-competitive antagonism for
orthosters in functional assays, where only the maximal
effect attenuates as the concentration of an alloster
increases while the dissociation constant for the agonist
stays constant. This happens for activity when constant c
is unity. An example is shown in Figure 4B. Note, that in
TCM occupancy, alloster effects can never be non-com-
petitive-like, i.e., with reduced activity and fixed EC50.
In a second form, S-liganded conformations, RS and
MRS, move tacitly to R*S and MR*S as source of activity.
This reaction scheme gives us models of activity and oc-
cupancy that behave in an identical manner as their distri-
bution equations are identical. This reaction scheme
includes enhancement for constant c > 1 and with ceiling
when Am⋅M > 1 and competitive inhibition when c < 1,
but with a ceiling effects for both binding and activation
by an alloster when c⋅Am⋅M > 10, Figure 4D and 4F. This
model is identical to the uncompetitive reaction scheme.
In a third form, all liganded conformations, i.e., RS,
MR, and MRS, are sources of activity, Figure 2B. InEXOM, this is the basic TCM. TCM sub-type 3 may
simulate allo-agonism for activity, but without ceiling
effects as indicated by black circles for limiting EC50
values as M→ ∞, Figure 4G-I.
Since the term “competitive inhibition”, according to
an informative review [48], meant inhibition through an
overlap or steric hindrance at binding sites [58], the term
“allosteric inhibition” was used from the start of the
1960s merely to indicate negative feedback different
from competitive inhibition. Nothing more. TCM with
its two remote binding sites has no mutual exclusion by
steric hindrance or by overlap. Meanwhile, TCM may
still simulate “competitive inhibition”, either by its un-
competitive form as shown in Figure 3F, or by mutual
exclusion of triple complex MRS through remote or inter-
molecular conformational changes, not shown. Thus,
TCM has allosteric inhibition in the MWC-sense.
“Competitive inhibition” by mutual exclusion in TCM
requires that the cooperative binding constant c goes to
insignificantly small values, thus preventing detectable
levels of MRS and of its tacitly active form, MR*S. Such
allosteric mutual exclusion, as one type II competitive
inhibition ([18], chapter 2) has been cartooned ([58],
Figure III-1, panel 5). Thus, as “allosteric” solely refer
to ligand binding at remote, non-overlapping binding
sites and without steric hindrance, “allosteric” becomes
a pleonasm in “allosteric ternary complex model”, ATCM,
as TCM is defined by having two, non-overlapping bind-
ing sites without steric hindrance. As both acronyms cover
the exact same model, it remains a matter of taste using
either ATCM or TCM. Contrary, the signifier “allosteric”
in “allosteric transition” [48] becomes indicative for
two-state models as MWC and ATSM, involving cTSM.
Comparison of simulations from ATSM and EXOM
A comparison is made between ATSM and EXOM
simulations of concentration-responses of activity with
orthoster concentration as independent variable and
with varying alloster concentration M. Thus, the follow-
ing are principal statements about parameter influences
on initial and maximal efficacies, on ceiling effects for
enhancement, competitive and mixed inhibition, on allo-
agonism and -synergy, as well as on apparent dissoci-
ation constant EC50. To simplify the comparison, EXOM
slope factor n is assumed unity. The results reveal a few
crucial differences between the two models even based
on homologous parameters as As, Am, a, c, and d.
As indicated above, IntEff for EXOM is dependent on
parameter b, while for ATSM it is dependent on both b
and L. For ATSM, MaxEff is dependent on L⋅a, whilst
EXOM-MaxEff is only dependent on a. Thus, when
comparing ATSM and EXOM, choice of values for a
and b in EXOM should match with values for L⋅a and
L⋅b in ATSM. Accordingly, in selection of parameter
Figure 4 Simulations from four sub-models of the ternary-complex model, TCM. For sub-model definitions see Table 2. Parameters As and
Am, equilibrium association constants for ligands S and M, are kept at unity. Parameter c, the cooperativity constant for binding, is varied by a
factor 103 in three steps for each sub-model as indicated in the panels. Red curves indicate orthoster concentration-response curves in the
absence of an alloster. In all panels the alloster M concentration is varied in four steps: in panels A-I by a factor 102 from 1x10-2 to 1x104; in
panels G-K by a factor 10 from 1x10-2 to 1x101 and in panel L by a factor 102 from 1x10-3 to 1x103. Green curves with circles show the actual
EC50 and the black circle represents the position of a limiting EC50 for M→ ∞.
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Figure 5 Simulations of concentration-response relations for
ATSM and EXOM. The parameters As and Am are both kept at unity,
while parameter L is 10-2 for all ATSM simulations in order to keep
spontaneous activity insignificant and n for all EXOM simulations is =
1. Parameter c, the binding cooperativity constant, is varied in three
steps by multiplying with a factor 103 from 10-3 to 103 as indicated
in the panels. Parameter a is 5000 in all ATSM panels except for
panels M-P where it is 500. For EXOM, parameter a is 50 in all panels
except for panels Q-S where it is 5. For ATSM, parameter b is 1 in
panels A-C, and 50 in the rest of panels G-V. For EXOM, parameter b
is 0.01 in panels D-F, and 0.5 in the rest of panels J-Z. Parameter d is
1 in all panels except in panels T-Z where it is 3x10-3. All red curves
have no alloster present, i.e., concentration of M = 0. M is varied in
four steps. In panels A-F by a factor 100 from 2x10-4 to 2x102; in
panels G-S by a factor 10 from 2x10-3 to 2x100; and in panels T-Z by
a factor 10 from 2x10-1 to 2x102. Green curves with circles show the
actual EC50 and the black circle represents the position of a limiting
EC50 for M → ∞. The black circle falls outside the orthoster
concentration range, 10-6 to 102, in panels S and Z with limiting
EC50 values of 250 and 1304.
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chosen as 0.01 in order to suppress spontaneous activity,
values for a and b in EXOM are chosen 100 fold higher
in ATSM, Figure 5.
IntEffs for both ATSM and EXOM are always com-
pletely independent of As, a, c, and d. ATSM-IntEff is
dependent on L and b⋅Am⋅M. For more details see anno-
tated Table 3. EXOM-IntEff only depends on b⋅Am⋅M.
Allo-agonism is a lift in the IntEff when supplying an
alloster even before an orthoster is added. Various forms
of allo-agonism are shown in Figure 5G-Z and with ceil-
ing effects indicated by black circles for the limiting
EC50 values as M → ∞. Allo-agonism is often seen in
studies with small molecule allosters [59]. Allo-agonism
takes effect in both models when both b and b⋅Am⋅M
are larger than unity. Furthermore, ATSM may simulate
spontaneous activity before any ligand is added. Simula-
tion of detectable spontaneous activity starts at values of
L above 10-2. This possibility is excluded from the
EXOM theory.
MaxEff in ATSM is dependent on L⋅a and b⋅c⋅d⋅Am⋅M,
Table 3, while MaxEff in EXOM is dependent on a
and c⋅d⋅Am⋅M. In comparison, EXOM-MaxEff demon-
strates complete independence of b, which is some-
what inconsistent. The independence is due to the
definition of parameter d (β) in EXOM, where an alloster
only affects the efficacy of an orthoster with no reci-
procity. Thus, synergy and mixed inhibition are different
between ATSM and EXOM, since the MaxEff-ATSM has
both parameter b and d involved while EXOM only
depends on d.
As already indicated, more details on parameter influ-
ences on IntEff, enhancement, allo-agonism, allo-synergy,
MaxEff, and mixed inhibition are given in comments
to Table 3.
Table 3 Conditions for alloster effects on initial efficacy and maximal efficacy in ATSM
Assumptions
for product
Reduced equation Lower level
product assumptions
Reduced equation




on product ofparameters ⋅[M]
possible allo-agonism of IntEff for [orthoster]→ 0: L/[L+((1+Am⋅ M)/(1+b⋅Am⋅ M))]
b⋅Am⋅ M >> 1 L⋅b⋅Am⋅M = X Am⋅M >> 1 L⋅b /(L⋅b +1) L⋅b vs 1
X/(X+1+Am⋅ M) Am⋅M = 1 L⋅b /(L⋅b +2) L⋅b vs 2
Am⋅M << 1 L⋅b /(L⋅b +1) L⋅b vs 1
b⋅Am⋅ M = 1 L⋅2/(L⋅2+1+Am⋅ M) Am⋅ M >> 1 L⋅2/(L⋅2+Am⋅ M) L⋅2 vs Am⋅ M
Am⋅ M = 1 L/(L+1) L vs 1
Am⋅ M << 1 L⋅2/(L⋅2+1) L⋅2 vs 1
b⋅Am⋅ M << 1 L/(L+1+Am⋅M) Am⋅ M >> 1 L/(L+Am⋅ M) L vs Am⋅ M
Am⋅ M = 1 L/(L+2) L vs 2
Am⋅ M << 1 L/(L+1) L vs 1
possible allo-synergy of MaxEff for [orthoster]→∞ : L⋅a/[L⋅a+((1+c⋅Am⋅M)/(1+b⋅c⋅d⋅Am⋅M))]
b⋅c⋅d⋅Am⋅M >> 1 with L⋅a⋅b⋅c⋅d⋅Am⋅M =Y c⋅Am⋅M >> 1 L⋅a⋅b⋅d/(L⋅a⋅b⋅d+1) L⋅a⋅b⋅d vs 1
Y/(Y+1+c⋅Am⋅M) c⋅Am⋅M = 1 L⋅a⋅b⋅d/(L⋅a⋅b⋅d+2) L⋅a⋅b⋅d vs 2
b⋅d >> 1
c⋅Am⋅M << 1 Y/(Y+1) Y vs 1
b⋅d >>> 1
b⋅c⋅d⋅Am⋅M = 1 with L⋅a⋅2 = Z c⋅Am⋅M >> 1 Z/(Z+c⋅Am⋅M) Z vs c⋅Am⋅M
Z/(Z+1+c⋅Am⋅M) c⋅Am⋅M = 1 L⋅a/(L⋅a+1) L⋅a vs 1
b⋅d = 1
c⋅Am⋅M << 1 L⋅a⋅2/(L⋅a⋅2+1) L⋅a⋅2 vs 1
b⋅c⋅d⋅Am⋅M << 1 L⋅a/(L⋅a+1+c⋅Am⋅M) c⋅Am⋅M >> 1 L⋅a/(L⋅a+c⋅Am⋅M) L⋅a vs c⋅Am⋅M
c⋅Am⋅M = 1 L⋅a/(L⋅a+2) L⋅a vs 2
b⋅d >> 1
c⋅Am⋅M << 1 L⋅a⋅/(L⋅a+1) L⋅a vs 1
Initial and maximal response for ATSM with orthoster concentration as independent variable with an interfering alloster. M or [M] stands for alloster concentration.
Conditions are listed with decreasing number of parameters from column 1 to 5 for products of M and parameters that affect the initial efficacy, IntEff, at very low
concentrations of orthoster, S, and the final maximal efficacy, MaxEff, at very high concentrations of S.
All conclusions for IntEff and MaxEff of ATSM are similar for the EXOM with the following exceptions: for EXOM 1) parameter L is replaced with 1in all statements
for ATSM and 2) parameter b disappears out of all MaxEff statements as listed for ATSM.
Below are further details about effects of parameters and alloster concentration on IntEff and MaxEff for ATSM and EXOM.
Initial efficacy. IntEff for ATSM or spontaneous activity:
For b = 1, IntEff = L/(L+1) and independent of the value of Am⋅M.
For b > 1, IntEff > L/(L+1). With increasing values of Am⋅M above 1 the IntEff increases towards a ceiling value of L⋅b/(L⋅b+1), equal allo-agonism. For decreasing
values of Am⋅M below 1, the IntEff goes towards L/(L+1).
For b < 1, IntEff < L/(L+1). With increasing values of Am⋅M above 1 the IntEff reduces towards a ceiling value of L⋅b/(L⋅b+1). For decreasing values of Am⋅M below
1, the IntEff increases towards L/(L+1).
Allo-agonism above spontaneous activity in ATSM, L/(L+1), is given by L⋅b/[L⋅b+1+1/(Am⋅M)], when both b⋅Am⋅M >> 1 and also parameter b > 1. The ceiling value
of this allo-agonism is L⋅b/(L⋅b+#), where # is a value between 1 or 2, depending on the value of Am⋅M.
IntEff for EXOM:
Allo-agonism in EXOM is always given by b/[b+1+1/(Am⋅M)], and going towards zero for b→ 0, independent of the value for b⋅Am⋅M, and with a ceiling level of b/
[b+¤], where ¤ is a value between 1 or 2, depending on the value of Am⋅M. Examples of ceiling effects and their absence in ATSM and EXOM are shown in
Figure 5. For 1/(Am⋅M) >> b+1 in EXOM, IntEff goes towards 0 if b < 1, while for 1/(Am⋅M) << b+1, IntEff approaches b/(b+1) as its ceiling level.
Maximal efficacy. MaxEff for ATSM:
When b⋅c⋅d⋅Am⋅M >> 1 and as long as c⋅Am⋅M ≥ 1, ATSM-MaxEff is always dependent on the product b⋅d and independent of the value of c⋅Am⋅M.
For b⋅d = 1, MaxEff = L⋅a/(L⋅a+1), independent of c⋅Am⋅M.
For b⋅d > 1, MaxEff > L⋅a/(L⋅a+1), = synergy. With increasing values of c⋅Am⋅M above 1, the MaxEff increases towards a ceiling value of 100%, i.e., above L⋅a/(L⋅a
+1) if L⋅a >> 1. For decreasing values of c⋅Am⋅M below 1, the MaxEff goes towards L⋅a/(L⋅a+1).
For b < 1, MaxEff < L⋅a/(L⋅a+1). With increasing values of c⋅Am⋅M above 1 the MaxEff reduces towards a ceiling value of L⋅a/(L⋅a+1) . For reducing values of
c⋅Am⋅M below 1, the MaxEff increases towards L⋅a/(L⋅a+1).
More details on dependence of MaxEff-ATSM on parameter combination are listed in the table.
As mentioned above, for b⋅c⋅d⋅Am⋅M >> 1, and c⋅Am⋅M ≥ 1, MaxEff is always independent of the value of c⋅Am⋅M.
MaxEff for EXOM:
MaxEffs for EXOM are as well as for ATSM dependent on c⋅d⋅Am⋅M. Further, for c⋅Am⋅M >> 1 when d >> 1, EXOM-MaxEff goes to 100%, while for c⋅Am⋅M >> 1 but
with c⋅d⋅Am⋅M << 1, it is determined by a/(a+c⋅Am⋅M). When c⋅Am⋅M ≤ 1 and c⋅d⋅Am⋅M >> 1, EXOM-MaxEff goes to 1, while for d << 1, it goes to zero.
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Table 4 Parameter ratios from best-fits with ATSM and





Parameters ratios from best fits to concentration-
response curves for orthosters at three different
concentrations of allosters
b c d Am
ATSM 1 4.9 3.4 3.2 1.8
EXOM 46 1.9 3.0 2.6
ATSM 2 2.8 97 11 15
EXOM * 50 17 3.0 84
ATSM 3 1.6 9.2 16 1.5
EXOM 26 35 33 3.8
Each single parameter ratio from best fits with ATSM or EXOM is adapted from
analysis of three sets of data in the literature, data-figures 1 to 3, see last
section in Methods for references. Each data set consists of four
concentration-response curves, where one curve is an orthoster concentration-
response curve without an alloster present and the three other curves are
orthoster concentration-responses experimentally obtained at three different
alloster concentrations.
Parameters a and As for both ATSM and EXOM were initially determined by
model-fits to the basic orthoster concentration-response curves without an
alloster present. Obtained values for a and As were inserted in the model
equations, which were then use for fitting to experimental data of the
parameters b, c, d, and Am in the theories. Each number in the table is a ratio
between best-fit values with the largest deviation between two of three
results from fits for the single parameter to three concentration-response
curves at different alloster concentrations.
* For responses indicating spontaneous activity as in data-figure 2, evaluation
by EXOM theory was performed by assuming a level of 9% spontaneous
activity, thus fitting the EXOM distribution equation to 91% activity for all
three alloster concentrations, 0.03, 0.1, and 0.3 μM ([37]). For ATSM used on
data-figure 2, spontaneous activity was implemented by setting L/(1 + L) =
0.09. For data-figures 1 and 3a value of 0.01 was selected for L.
For a more detailed explanation of how the presented parameter ratios are
obtained, see last section in Methods.
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positive allosteric modulators (PAMs) are hallmarks and
often detected in experiment [17,35-37]. These ceiling
effects appear for Am⋅M > 1, panels A, D, G, J, M, Q, T,
and X in Figure 5. Ceiling effects for competitive inhib-
ition are determined by cooperative binding constant c < 1
and appears for c⋅Am⋅M > 10, and best seen for b⋅d = 1,
panels C, F, I, L, P, S, V, and Z in Figure 5.
The ATSM was rejected as model for allo-competitive
inhibition by gallamine at muscarinic subtype M2 recep-
tors [20]. Meanwhile, both ATSM and EXOM can nicely
simulate competitive inhibition with values of c low
enough to keep the parameter products b⋅c⋅d⋅Am⋅M for
ATSM and c⋅d⋅Am⋅M for EXOM less than 10, exempli-
fied in Figure 5C and F.
Allo-synergy, seen in the presence of allosters as a lift in
MaxEff above MaxEff for othosters alone, is now com-
monly described for agonistic-PAMs as well [5,8,25,36]. In
ATSM, these characteristics of PAMs with MaxEff above
maximal response for endogenous ligands alone may be
simulated with values of b and d when their product is > 1,
Figure 5M-N, while EXOM can simulate allo-synergy for
d > 1, not shown. Mixed inhibition, appearing as values of
MaxEff lower than MaxEff with orthosters alone in the
presence of NAMs, including pure non-competitive inhib-
ition, may be simulated for b⋅d < 1 in ATSM, Figure 5U,
and for d < 1 in EXOM, Figure 5Y. Published examples of
negative allosteric effects are now increasing as more inter-
est is invested in development of NAMs [12,32,60].
In both allo-synergy and allo-inhibition, parameter c,
as its value is lowered, will narrow the gap between
MaxEff in the presence and absence of an alloster; com-
pare panels M-P and panels T-Z in Figure 5.
The lack of effect of parameter b on MaxEff in EXOM
clearly weakens the theory, even though additional
details have been presented on the behaviour of EXOM
[34]. A variant of EXOM has been developed with
lumped parameters thus avoiding the problem of a miss-
ing effect of parameter b in MaxEff [24].
Comparison of best-fit analyses to experimental data for
ATSM and EXOM
Results from analysis of experimental data with ATSM
and EXOM are listed in Table 4. Ideally parameters in a
theory should manage to stay constant when the theory
is fitted to different data sets of the same experimental
concentration-response system; for instance at increas-
ing alloster concentrations. Therefore, the more the
ratios in Table 4 for each single parameter deviate from
unity in the present analysis, the worse is its model’s
credibility.
Both ATSM and EXOM have problems with a convin-
cing determination of parameters fitted to data in data-
figure 2. However, ATSM still seems to give the best resultbased on an overall evaluation of ratios for all four para-
meters from the three data sets of data-figure 2, Table 4.
Although exponentiation in form of a Hill coefficient
may also be invoked for both models, such exponentiation
was omitted in the present analysis. Also, an interpretation
and detailed discussion of the actually obtained parameter
values are beyond the scope of this paper.
Thus, based on the ratios in Table 4, it may be con-
cluded that ATSM seems to be better than EXOM at
evaluating possible parameter values with a requirement
of consistency when determined at 3 different alloster
concentrations, since in general most of the ratios are
closer to unity when employing the ATSM.
Conclusion
In a beautiful review, non-mechanistic EXOM against
mechanistic ATSM is debated and further contrasted
with an empirical general description of synagic behav-
iour of allosters in different experimental setups [17].
When system information is limited, analyses of allo-
steric behaviour by operational, empirical and mathem-
atical approaches as Hill’s exponentiation are still valid.
Meanwhile, analysing systems of allosteric synagics as
discussed here, the best description of allosteric effects is
by Hall’s millennium milestone mechanical model
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mechanistic models as the ATSM are given with its
assumptions, which usually both exclude more than two
binding sites and multi-steps or parallel pathways. The
ATSM may still replace the EXOM as a phenomeno-
logical model by applying assumptions similar to those
for EXOM. For the future, allosteric models should be
developed based on ATSM and implicating multi-
binding and diverse pathways of receptor activation
when needed. Thus, instead of switching to non-
mechanistic approaches as EXOM or reduce require-
ments for the basic TCM to analyse such systems
[20,26], phenomenological or extended forms of the
ATSM should be preferred (e.g., [25]).
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